Rallybio Corporation cash flow to debt ratio of -16.94K% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Rallybio Corporation's free cash flow has increased -39.51% from $-49.28M last year to $-29.81M, signaling increasing performance

Rallybio Corporation's debt to equity ratio is 0.00, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.

Rallybio Corporation's debt has decreased relative to shareholder equity from 0.00 last year to 0.00 today, signaling strengthened financials

Rallybio Corporation has negative EBITDA, making leverage ratio unreliable

Rallybio Corporation earns at least as much interest as it pays. Interest obligations are fully covered.

Rallybio Corporation's profit margin has increased (-89.97%) in the last year from -9.08K% to -911.07%, signaling increasing performance

Rallybio Corporation's short-term assets of $61.25M exceed its short-term liabilities of $4.22M

Rallybio Corporation's return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Rallybio Corporation's return on equity of -14.39%, is lower than 15.00%, indicating bad performance

Rallybio Corporation's operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Rallybio Corporation had positive net income in only 0.00 out of 5 years, indicating unstable earnings

Rallybio Corporation has negative free cash flow, indicating the company is burning cash rather than generating it

Rallybio Corporation has negative free cash flow, indicating cash burn

Rallybio Corporation's yearly earnings has increased -84.46% since last year from $-57.77M to $-8.98M, signaling increasing performance

Rallybio Corporation's yearly revenue has increased 34.91% since last year from $636.00K to $858.00K, signaling increasing performance

ROIC -55.77% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Rallybio Corporation has insufficient revenue history to calculate 3-year revenue CAGR.

Rallybio Corporation had revenue growth in 5.00 out of 5 years, indicating consistent revenue performance

Rallybio Corporation had positive ROE in only 0.00 out of 5 years, indicating inconsistent returns on equity

Rallybio Corporation has insufficient data to evaluate this check.

Rallybio Corporation has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Rallybio Corporation is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Rallybio Corporation has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Rallybio Corporation has insufficient data to evaluate this check.

Rallybio Corporation has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Rallybio Corporation has a price-to-book ratio of 1.81x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Rallybio Corporation has a price-to-sales ratio of 108.16x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue